

kb ladder (BRL). The results of detection of mouse α -interferon receptor mRNA by RT-PCR in the samples described above are shown in Figure 15B. The specific human HPRT mRNA was also detected in the other tissues tested (brain, kidney and heart) derived from the 4-3 mouse. Comparable steady-state levels of mouse and human HPRT mRNA were detected in the liver of yHPRT-containing progeny. These results indicate that the uptake of as much as 13 megabases of yeast genomic DNA was not detrimental to proper development, germline transmission or gene expression.

Please insert the sequence listing (pages 1-8) submitted herewith at the end of the application after the abstract.

IN THE CLAIMS

Please cancel claims 2-10, 12, 13, 17-24, 26, 28-33, 36-39, 41-49, 51, 53, 55, 56, 58, 59, 61-66, 69, 71, 73, 74, and 76-78 without prejudice.

REMARKS

Applicants have amended the specification to make reference to a priority claim under 35 U.S.C. §120 to U.S. Application Nos. 08/031,801 filed March 15, 1993.

Applicants have amended the specification to insert a paper copy of the Sequence Listing. The Sequence Listing

is identical to that filed January 10, 2003 in United States Application 08/031,801 ("the '801 application"), from which the instant application claims benefit. This amendment does not include new matter.


Pursuant to 37 C.F.R. § 1.821(e), applicant requests that the Patent Office use the computer readable form (CRF) copy of the Sequence Listing filed January 10, 2003 in the '801 application in the present application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the CRF that will be used for the instant application. Applicants also submit herewith a statement verifying that the enclosed paper copy of the Sequence Listing and the CRF copy of the Sequence Listing submitted January 10, 2003 in the '801 application are the same and do not include new matter.

Applicants additionally amended the specification to add sequence identifiers where appropriate. None of these amendments introduces new matter. Their entry is requested.

Applicants have canceled claims 2-10, 12, 13, 17-24, 26, 28-33, 36-39, 41-49, 51, 53, 55, 56, 58, 59, 61-66, 69, 71, 73, 74, and 76-78 without prejudice. Applicants

expressly reserve the right to pursue any cancelled subject matter in subsequent applications that claim benefit from this application. As such, claims 1, 11, 14-16, 25, 27, 34, 35, 40, 50, 52, 54, 57, 60, 67, 68, 70, 72, and 75 are pending in this application.

Respectfully submitted,



Jane T. Gunnison
Reg. No. 38,479
Attorney for Applicant

R. Minako Pazdera
Reg. No. 46,984
Agent for Applicant
FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax: (212) 596-9090